The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Its critical for healthcare providers to insure that providing quality care is not just a notion but rather a reality. For too long the majority of providers have not focused on the idea that the higher the quality the lower the cost of providing services. Providers will that realize that reducing errors,...
On August 2, 2007, CMS decided that ambulatory surgery centers (ASCs) will be paid in CY2008 using APCs, the system used to reimburse hospital outpatient departments. Freestanding ASCs will be paid 65% of the rates for HOPDs that were published in November, 2007. But how will CMS, MedPAC, and the Congress...
This is a rapidly growing market segment, far larger than their indication for schizophrenia in this age group, that could be a very positive influencer on market expansion and sales growth.
I formerly worked at Pasteur Merieux Connaught and have quite a bit of experience with meningococcal meningitis vaccines. The largest number of cases occur in teenagers and young adults, the second highest group is the pediatric population. This is a deadly disease that can spread quickly among populations...
So this is Wyeth's grand strategy to protect it's Protonix Franchise? It may be able to keep the generic erosion to around 20% versus 90%. I am not impressed, and feel that Teva's strong relationship with the Distribution networks will blunt most of the positive impact, pharmacists will call and switch...
Those programs that have a large census in the nursing home NH will be at risk for decreased revenues and closer scrutiny of their programs. Growth estimates for all programs that center their services on NFs will need to change their focus.
This is a big hit for Pfizer - a costly product they licensed due to lack of good pipeline products. Unfortunatley, I don't think they anticipated the issues surrounding the complexity of inhaled insulin, properly marketed the product, or did enough research on the patient side (ie compliane,...